ERBB2 and breast cancer: With the promising response rate of ADC in HER2‐low BC patients,12, 36, 37, 38, 39 we hypothesised that refining the definition of HER2‐low‐positive class with precise scoring criteria for this group will lead to better scoring concordance levels and better personalisation of ADC therapy.